Page 101 - 《中国药房》2025年4期
P. 101

7种抗肿瘤药物血药浓度测定方法建立及临床应用                                                       Δ



          吕锦绣 ,颜 楠,徐文俊,赵 静,朱 华,杭鹏洲(苏北人民医院药学部,江苏 扬州 225001)
                                                       #
                *
          中图分类号  R917      文献标志码  A      文章编号  1001-0408(2025)04-0475-07
          DOI  10.6039/j.issn.1001-0408.2025.04.15


          摘  要  目的  建立同时测定人血浆中7种抗肿瘤药物(伊立替康、卡培他滨、紫杉醇、多西他赛、他莫昔芬、来曲唑和甲氨蝶呤)血
          药浓度的方法并应用于临床。方法  血浆样品以含0.1%甲酸的甲醇-乙腈混合液(1∶1,V/V)沉淀蛋白后,以各待测成分的氘代同
          位素为内标,采用液相色谱-串联质谱(LC-MS/MS)技术检测。以 Agilent Eclipse Plus C18为色谱柱,以水(含 0.1% 甲酸和 0.04%
          5 mmol/L甲酸铵)为流动相A相、乙腈(含0.1%甲酸)为流动相B相进行梯度洗脱,流速为0.6 mL/min,柱温为40 ℃,进样量为10
          μL,分析时间为5.5 min;采用电喷雾离子源在正、负离子模式下以多反应监测模式进行测定,用于定量分析的离子对分别为m/z
          587.1→167.1(伊立替康)、m/z 360.1→244.1(卡培他滨)、m/z 876.4→308.0(紫杉醇)、m/z 830.3→304.2(多西他赛)、m/z 372.1→129.1
         (他莫昔芬)、m/z 284.1→242.1(来曲唑)、m/z 455.0→308.0(甲氨蝶呤)。选择我院97例恶性肿瘤患者,采用上述方法测定其血浆中
          7种抗肿瘤药物的血药浓度。结果  伊立替康、卡培他滨、紫杉醇、多西他赛、他莫昔芬、来曲唑和甲氨蝶呤的线性范围分别为2~
          1 000 ng/mL(r=0.994 3)、20~10 000 ng/mL(r=0.997 5)、2~1 000 ng/mL(r=0.997 9)、1~500 ng/mL(r=0.995 8)、1~500 ng/mL
         (r=0.995 2)、1~500 ng/mL(r=0.996 4)、10~5 000(r=0.997 7);定量下限分别为2、20、2、1、1、1、10 ng/mL;批内精密度的RSD为
          0.08%~14.86%(n=6),批间精密度的 RSD 为 1.51%~11.55%(n=3),准确度为 89.17%~114.93%(n=6);基质效应为 89.89%~
          119.74%(n=6);稳定性试验的RSD为1.98%~14.88%(n=6)。临床应用结果显示,伊立替康、卡培他滨、紫杉醇、多西他赛的平均
          血药浓度分别为 704.09、909.40、36.45、150.43 ng/mL,变异系数分别为 25.24%、62.65%、122.69%、92.27%。结论  所建 LC-MS/MS
          法操作简单、分析时间短,可用于恶性肿瘤患者体内7种常用抗肿瘤药物血药浓度的测定。
          关键词  抗肿瘤药物;治疗药物监测;血药浓度;液相色谱-串联质谱技术

          Determination method of plasma concentrations of 7 anti-tumor drugs and its application
          LYU Jinxiu,YAN Nan,XU Wenjun,ZHAO Jing,ZHU Hua,HANG Pengzhou(Dept.  of  Pharmacy,  Northern
          Jiangsu People’s Hospital, Jiangsu Yangzhou 225001, China)

          ABSTRACT     OBJECTIVE  To  establish  a  method  for  simultaneous  determination  of  7  anti-tumor  drugs  (irinotecan,
          capecitabine,  paclitaxel,  docetaxel,  tamoxifen,  letrozole  and  methotrexate)  in  human  plasma  and  apply  it  to  the  clinic.
          METHODS  After  precipitating  with  a  methanol-acetonitrile  mixture  (1∶ 1,  V/V)  containing  0.1%  formic  acid,  liquid
          chromatography-tandem mass spectrometry (LC-MS/MS) was used to determine the plasma concentration, using deuterium isotopes
          of  each  analyte  as  internal  standards.  The  chromatography  was  performed  on  the Agilent  Eclipse  Plus  C18  column  with  a  gradient
          elution of water (containing 0.1% formic acid+0.04% 5 mmol/L ammonium formate) as mobile phase A and acetonitrile (containing
          0.1%  formic  acid)  as  mobile  phase  B. The  flow  rate  was  0.6  mL/min,  and  the  column  temperature  was  set  at  40  ℃. The  sample
          size  was  10  μL,  and  the  analysis  lasted  for  5.5  min.  Electrospray  ionization  was  used  in  positive  and  negative  ion  mode,  and
          multiple reaction monitoring mode was used. The ion pairs used for quantitative analysis were m/z 587.1→167.1 (irinotecan), m/z
          360.1→244.1 (capecitabine),  m/z  876.4→308.0 (paclitaxel),  m/z  830.3→304.2 (docetaxel),  m/z  372.1→129.1 (tamoxifen),  m/z
          284.1→242.1 (letrozole), and m/z 455.0→ 308.0 (methotrexate). A total of 97 patients with malignant tumors in our hospital were
          selected  to  measure  the  plasma  concentrations  of  7  anti-tumor  drugs  using  the  above  method.  RESULTS  The  linear  ranges  of
          irinotecan,  capecitabine,  paclitaxel,  docetaxel,  tamoxifen,  letrozole  and  methotrexate  were  2-1  000  ng/mL (r=0.994  3),  20-10
          000  ng/mL (r=0.997  5),  2-1  000  ng/mL (r=0.997  9),  1-500  ng/mL (r=0.995  8),  1-500  ng/mL (r=0.995  2),  1-500  ng/mL
         (r=0.996 4), 10-5 000 (r=0.997 7), respectively. The quantitative lower limits were 2, 20, 2, 1, 1, 1 and 10 ng/mL; RSDs of
                                                             intra-assay  precision  were  0.08%-14.86% (n=6).  RSDs  of
             Δ  基金项目 苏 北 人 民 医 院 青 年 托 举 专 项 青 年 基 金(No.     inter-batch  precision  were  1.51%-11.55% (n=3),  and  the
          SBQN22012);苏北人民医院院级扶持技术项目(No.FCJS202313)           accuracies  were  89.17%-114.93%  (n=6).  The  matrix
             *第一作者 药师,硕士。研究方向:治疗药物监测。E-mail:
                                                             effects  ranged  from  89.89%-119.74% (n=6).  RSDs  of  the
          jinxiulv2022@163.com
                                                             stability  tests  were  1.98%-14.88% (n=6).  The  results  of
             # 通信作者 研究员,博士。研究方向:心血管药理学与临床药学。
          E-mail:hangpengzhou@163.com                        clinical  application  showed,  the  average  plasma  concentrations  of


          中国药房  2025年第36卷第4期                                                 China Pharmacy  2025 Vol. 36  No. 4    · 475 ·
   96   97   98   99   100   101   102   103   104   105   106